ClinicalTrials.gg
CompletedNCT01515306Updated Mar 8, 2022Results posted

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

A Phase 2 interventional study of ramucirumab (IMC-1121B) and paclitaxel in Malignant Solid Tumor, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-08.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors.

Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.

02

Conditions studied

  • Malignant Solid Tumor

Keywords

  • Advanced Malignant Solid Tumors
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has histologic or cytologic documentation of a malignant solid tumor
  • Has an advanced solid tumor that is to standard therapy or for which no standard therapy is available
  • Part A only: Has had 0-1 prior taxane-containing treatment regimens (including taxane monotherapy), which must have been completed at least 6 months before the first dose of study medication (prior bevacizumab is allowed)
  • Part B only: Prior bevacizumab- and taxane-containing treatment regimens (including taxane monotherapy) are allowed, provided these regimens have been completed at least 6 months before the first dose of study medication
  • Has resolution to Grade ≤ 1 of all toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy, which must not have exceeded Grade 1, by the National Cancer Institute , Version 4.0 (NCI-CTCAE v 4.0)
  • Has an Performance Status (ECOG PS) of 0 - 2
  • Has adequate hematologic function. Blood transfusion is allowed but must be completed 48 hours before study drug administration
  • Has adequate hepatic function ( ≤ 1.5 times the [ULN], [AST] and alanine transaminase [ALT] ≤ 1.5 x ULN
  • Has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN, the calculated (CrCl) should be ≥ 40 milliliter/minute (mL/min)
  • Urinary protein is \<2+ on dipstick or routine urinalysis (UA)
  • Must have adequate coagulation function as defined by an (INR) of ≤ 1.5 and a partial thromboplastin time (PTT) or an activated PTT (aPTT) ≤ 1.5 x ULN
  • Eligible participants of agree to use adequate method of during the study period and for 12 weeks after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • Is receiving concomitant therapy with inhibitors or inducers of cytochrome P450, CYP2C8, CYP3AY and/or isoenzymes
  • Are currently enrolled in, or discontinued within the last 14 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Has received a monoclonal antibody within 42 days prior to first dose of study medication
  • Has received radiotherapy within 14 days prior to first dose of study medication
  • Has received cytotoxic chemotherapy within 21 days (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study medication
  • Has a cardiac (LVEF) not within institutional limits of normal on a multigated acquisition scan (MUGA) or echocardiogram
  • Is receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, targeted or other investigational anticancer therapy
  • Is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents. Aspirin use at doses up to 325 milligrams/day (mg/day) and analgesic agents with no or low bleeding risk are permitted
  • Has a history of uncontrolled hereditary or acquired bleeding or thromboembolic disorders
  • Has experienced any arterial thromboembolic event, including myocardial infarction (MI), unstable angina stroke or (TIA), within 6 months prior to first dose of study medication
  • Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to first dose of study medication
  • Has experienced a Grade 3 or 4 hemorrhagic event within 3 months prior to first dose of study medication
  • Has experienced peripheral neuropathy ≥ Grade 2 at any time prior to study entry
  • Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  • History of gastrointestinal perforation and / or fistulae within 6 months prior to randomization
  • Has an ongoing or active infection requiring treatment with intravenous antibiotics
  • Has a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to first dose of study medication
  • Has uncontrolled hypertension
  • Has symptomatic congestive heart failure
  • Has known brain or
  • Has known positive status for (HIV) infection or acquired immunodeficiency syndrome-related illness
  • Has known active drug or alcohol abuse that would affect participant's ability to comply with study treatment
  • Has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
  • Has had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study medication
  • Has an elective or planned major surgery during the course of the trial
  • If a primary cancer is non-small-cell lung cancer (NSCLC), participant has intratumor cavitation, radiologically documented evidence of major blood vessel invasion or encasement by cancer, or proximity of cancer to major airways
  • Has received prior ramucirumab (IMC-1121B) therapy
  • The participant has:

    • cirrhosis at a level of B (or worse)
    • cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part A: ramucirumab (IMC-1121B) and paclitaxel

    Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel Cycle 1: paclitaxel administered on Day 1 of 2-week cycle. Cycle 2 and beyond : ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.

    Biological: ramucirumab (IMC-1121B) · Drug: paclitaxel

  • Experimental
    Part B: ramucirumab (IMC-1121B) and paclitaxel

    Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle. Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4- week cycle. \*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A.

    Biological: ramucirumab (IMC-1121B) · Drug: paclitaxel

Interventions

  • ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.

    Also known as: LY3009806

  • paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.

06

What researchers measure

Primary outcomes

  1. Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 1: 0, 1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion

  2. Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 2

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion

  3. Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1

    Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion

  4. Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2

    Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion

  5. Part B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] as Monotherapy

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose.

    Time frame: Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72,168, 264, 336, 408, and 504 hours post ramucirumab infusion

Secondary outcomes

  1. Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] in the Presence of Paclitaxel

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose.

    Time frame: Cycle 2: 0, 1, 2, 2.5, 3, 6, 8, 25, 49, 73, 97, 169, 265 and 337 hours post ramucirumab infusion

  2. Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Ramucirumab in the Presence of Paclitaxel

    Dose-normalized Cmax was calculated from Cmax divided by the dose.

    Time frame: Cycle 2: 0, 1, 2, 2.5, 3, 6, 8, 25, 49, 73, 97, 169, 265 and 337 hours post ramucirumab infusion

  3. Part A: Immunogenicity of Ramucirumab in Combination With Paclitaxel - Number of Participants With Anti-Ramucirumab Antibodies

    Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

    Time frame: -1 hour on Day 1 of Cycle 2, and 30 days after last dose of study drug

  4. Part B: Immunogenicity of Ramucirumab as Monotherapy - Number of Participants With Anti-Ramucirumab Antibodies

    Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

    Time frame: 0 hour on Day 1 of Cycle 1, and 30 days after last dose of study drug

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestonePart A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without Paclitaxel
Started2416
Received at least 1 dose of study drug2416
Cycle 12416
Cycle 22115
Drug-drug interaction population210
Completed02
Not completed2414
Withdrew: Adverse event32
Withdrew: Progressive disease199
Withdrew: Withdrawal by subject12
Withdrew: Physician decision11

Outcome measures

PrimaryPart A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 1: 0, 1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion
Reported as:
Least squares mean · nanograms*hour/milliliter/milligram
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1
nanograms*hour/milliliter/milligramPart A: Paclitaxel Alone (Cycle 1)
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 129 (24.50 to 34.34)
PrimaryPart A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 2

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion
Reported as:
Least squares mean · nanograms*hour/milliliter/milligram
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 2
nanograms*hour/milliliter/milligramPart A: Paclitaxel + Ramucirumab (Cycle 2)
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 231.67 (26.58 to 37.73)
Statistical analysis
  • Part A: Paclitaxel + Ramucirumab (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 1.09 · 90% CI 0.93 to 1.29Ratio of Geo LS mean is AUC(0-∞) of Cycle 2/Cycle 1.
PrimaryPart A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion
Reported as:
Least squares mean · nanograms/milliliter/milligram
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1
nanograms/milliliter/milligramPart A: Paclitaxel Alone (Cycle 1)
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 118.84 (16.03 to 22.13)
PrimaryPart A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264 and 336 hours post paclitaxel infusion
Reported as:
Least squares mean · nanograms/milliliter/milligram
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2
nanograms/milliliter/milligramPart A: Paclitaxel + Ramucirumab (Cycle 2)
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 218.30 (15.54 to 21.56)
Statistical analysis
  • Part A: Paclitaxel + Ramucirumab (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 0.97 · 90% CI 0.83 to 1.13Ratio of Geo LS mean is Cmax of Cycle 2/Cycle 1.
PrimaryPart B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] as Monotherapy

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose.

Time frame:
Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72,168, 264, 336, 408, and 504 hours post ramucirumab infusion
Reported as:
Geometric mean · micrograms*hour/milliliter/milligram
Part B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] as Monotherapy
micrograms*hour/milliliter/milligramPart B: Ramucirumab Alone (Cycle 1)
Part B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] as Monotherapy55.3 ± 27
SecondaryPart A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] in the Presence of Paclitaxel

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose.

Time frame:
Cycle 2: 0, 1, 2, 2.5, 3, 6, 8, 25, 49, 73, 97, 169, 265 and 337 hours post ramucirumab infusion
Reported as:
Geometric mean · micrograms*hour/milliliters/milligram
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] in the Presence of Paclitaxel
micrograms*hour/milliliters/milligramPart A: Paclitaxel + Ramucirumab (Cycle 2)
Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-∞)] in the Presence of Paclitaxel55.4 ± 27
SecondaryPart A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Ramucirumab in the Presence of Paclitaxel

Dose-normalized Cmax was calculated from Cmax divided by the dose.

Time frame:
Cycle 2: 0, 1, 2, 2.5, 3, 6, 8, 25, 49, 73, 97, 169, 265 and 337 hours post ramucirumab infusion
Reported as:
Geometric mean · micrograms/milliliter/milligram
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Ramucirumab in the Presence of Paclitaxel
micrograms/milliliter/milligramPart A: Paclitaxel + Ramucirumab (Cycle 2)
Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Ramucirumab in the Presence of Paclitaxel0.384 ± 31
SecondaryPart A: Immunogenicity of Ramucirumab in Combination With Paclitaxel - Number of Participants With Anti-Ramucirumab Antibodies

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

Time frame:
-1 hour on Day 1 of Cycle 2, and 30 days after last dose of study drug
Reported as:
Count of participants · Participants
Part A: Immunogenicity of Ramucirumab in Combination With Paclitaxel - Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsPart A: Paclitaxel and Ramucirumab (Cycle 2)
Part A: Immunogenicity of Ramucirumab in Combination With Paclitaxel - Number of Participants With Anti-Ramucirumab Antibodies0
SecondaryPart B: Immunogenicity of Ramucirumab as Monotherapy - Number of Participants With Anti-Ramucirumab Antibodies

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

Time frame:
0 hour on Day 1 of Cycle 1, and 30 days after last dose of study drug
Reported as:
Count of participants · Participants
Part B: Immunogenicity of Ramucirumab as Monotherapy - Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsPart B: Ramucirumab Alone (Cycle 1)
Part B: Immunogenicity of Ramucirumab as Monotherapy - Number of Participants With Anti-Ramucirumab Antibodies0

Adverse events

Collected over Baseline, up to 8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Paclitaxel Alone (Cycle 1)—1/24 (4.2%)18/24 (75%)
Part A: Paclitaxel + Ramucirumab (Cycle 2)—6/21 (28.6%)21/21 (100%)
Part B: Ramucirumab Alone (Cycle 1)—0/16 (0%)8/16 (50%)
Part B: Ramucirumab + Paclitaxel (Cycle 2)—6/15 (40%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPart A: Paclitaxel Alone (Cycle 1)Part A: Paclitaxel + Ramucirumab (Cycle 2)Part B: Ramucirumab Alone (Cycle 1)Part B: Ramucirumab + Paclitaxel (Cycle 2)
ColitisGastrointestinal disorders0/240/210/161/15
ConstipationGastrointestinal disorders0/240/210/161/15
Large intestinal obstructionGastrointestinal disorders0/240/210/161/15
Device related infectionInfections and infestations0/240/210/161/15
PneumoniaInfections and infestations0/240/210/161/15
SepsisInfections and infestations0/240/210/161/15
HyponatraemiaMetabolism and nutrition disorders0/240/210/161/15
Back painMusculoskeletal and connective tissue disorders0/240/210/161/15
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/210/161/15
HypoxiaRespiratory, thoracic and mediastinal disorders0/240/210/161/15
Most frequent other events
Showing 10 of 105
Most frequent other events
EventPart A: Paclitaxel Alone (Cycle 1)Part A: Paclitaxel + Ramucirumab (Cycle 2)Part B: Ramucirumab Alone (Cycle 1)Part B: Ramucirumab + Paclitaxel (Cycle 2)
FatigueGeneral disorders1/2414/212/164/15
AnaemiaBlood and lymphatic system disorders3/2410/210/163/15
EpistaxisRespiratory, thoracic and mediastinal disorders0/247/210/166/15
DiarrhoeaGastrointestinal disorders1/248/211/163/15
HeadacheNervous system disorders2/247/210/162/15
Decreased appetiteMetabolism and nutrition disorders1/246/211/163/15
AlopeciaSkin and subcutaneous tissue disorders0/246/210/161/15
NauseaGastrointestinal disorders2/245/214/164/15
Oedema peripheralGeneral disorders0/245/211/164/15
ProteinuriaRenal and urinary disorders0/240/212/164/15

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Part A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without PaclitaxelTotal
<=18 years000
Between 18 and 65 years141024
>=65 years10616
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without PaclitaxelTotal
Female13922
Male11718
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without PaclitaxelTotal
Hispanic or Latino101
Not Hispanic or Latino231639
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without PaclitaxelTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White221537
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Part A: Paclitaxel and RamucirumabPart B: Ramucirumab With or Without PaclitaxelTotal
United States241640
08

Study locations

6 sites
  • ImClone Investigational Site
    Ann Arbor, Michigan 48109, United States
  • ImClone Investigational Site
    Detroit, Michigan 48202, United States
  • ImClone Investigational Site
    New Brunswick, New Jersey 08901, United States
  • ImClone Investigational Site
    Cleveland, Ohio 44195, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Mar 2013, 8 months.

Results were first posted in Jun 2014, 1 year 2 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Jan 24, 2012
StartActual
Jul 19, 2012
Primary completionActual
Mar 20, 2013
CompletionActual
Feb 22, 2021
Results delay requested
Apr 25, 2014
Results first posted
Jun 18, 2014
Last update
Mar 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01515306
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
Jul 19, 2012
Primary completion
Mar 20, 2013
Completion
Feb 22, 2021
Results posted
Jun 18, 2014
Last update
Mar 8, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion